ABL1 and amyotrophic lateral sclerosis: The potential role of c-Abl inhibition in ALS is strengthened by the finding that another c-Abl inhibitor, dasatinib (DrugBank Accession Number DB01254), was able to attenuate motoneuron loss, delay disease progression and extend the survival of mSOD1G93A ALS mice.